

mw. dr. I.M. Oving
- Functie Internist-oncoloog
- Afdeling / specialisatie Interne geneeskunde, Oncologie, Borstkliniek Oost-Nederland
Afspraak maken?
Aandachtsgebieden
- Interne geneeskunde
- Oncologie
BIG-nummer
89041100101
Wetenschappelijke publicaties en onderzoeken
-
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment
Boerrigter E, Benoist GE, Oort IM van , Verhaegh GW, Hooij O van , Groen L, Smit F, Oving IM, Mol P de, Smilde TJ.
Mol Oncol 2021; :doi: 10.1002/1878-0261.12933. Online ahead of print..
-
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
Ramshorst MS van , Voort A van der , Werkhoven ED van , Mandjes IA, Kemper I, Dezentjé VO, Oving IM.
Lancet Oncol. 2018; 19(12):1630-1640.
Publicatie openen -
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study
Ramshorst MS van, Werkhoven E van, Honkoop AH, Dezentjé VO, Oving IM, Mandjes IA, Kemper I, Smorenburg CH, Stouthard JM, Linn SC, Sonke GS.
Breast 2016 Epub 2016; 5:doi: 10.1016/j.breast.2016.07.017. .
Publicatie openen -
Safety analyses of the first 110 patients treated with dual HER2-blockade in the TRAIN-2 study
Ramshorst M van, Werkhoven E van, Honkoop A, Dezentje V, Oving IM, Mandjes I.
Eur J Cancer 2016; 57:S96:Suppl 2.